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Retinal pigment epithelial (RPE) cells are continually exposed to oxidative stress that contributes to protein misfolding,
aggregation and functional abnormalities during aging. The protein aggregates formed at the cell periphery are delivered
along the microtubulus network by dynein-dependent retrograde traﬃcking to a juxtanuclear location. We demonstrate that
Hsp90 inhibition by geldanamycin can eﬀectively suppress proteasome inhibitor, MG-132-induced protein aggregation in a way
that is independent of HDAC inhibition or the tubulin acetylation levels in ARPE-19 cells. However, the tubulin acetylation
and polymerization state aﬀects the localization of the proteasome-inhibitor-induced aggregation. These findings open new
perspectives for understanding the pathogenesis of protein aggregation in retinal cells and can be useful for the development
of therapeutic treatments to prevent retinal cell deterioration.
1. Introduction
Retinal pigment epithelial (RPE) cells are exposed to chronic
oxidative stress. They must constantly absorb light energy
and phagocyte lipid rich photoreceptor outer segment shed
from neural retina due to normal physiological visual cycle.
Oxidative stress refers to progressive cellular damage that
contributes to protein misfolding and functional abnormal-
ities in the RPE cells during cellular senescence [1]. The
accumulation of this damage in the postmitotic RPE cells
seems to be one of the key events in the development of age-
related macular degeneration (AMD), the leading cause of
blindness in the elderly in the developed countries. The RPE
cells ensure the survival of neural cells, rod, and cones. In
senescent RPE cells, this ability is reduced causing secondary
adverse eﬀects on the neural retina, ultimately leading to loss
of vision. Both intra- and extracellular aggregation processes
are crucial in cell degeneration and AMD [2].
Eﬃcient removal of misfolded proteins from cytoplasm
is critical for cellular survival and adaptation. However,
potentially toxic misfolded protein aggregates accumulate
during the aging process [3, 4]. Control of protein turnover
is particularly important in postmitotic cells, since the
accumulation of malfunctioning proteins may be highly
detrimental to the cells [5]. Once heat shock protein-
mediated protein folding fails, the misfolded proteins are
usually tagged with a ubiquitin (Ub) moiety that directs the
complex to the ubiquitin/proteasomal protein degradation
pathway (UPP) [6]. It is believed that the aggregation of
oxidized and ubiquinated proteins is due to a decline in
the proteasomal activity with age, and that this also occurs
in RPE cells [7–10]. Protein aggregates formed in the cell
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periphery are delivered along microtubulus network by
dynein-dependent retrograde traﬃcking to a juxtanuclear
location where they form aggresomes [11–13]. The devel-
opment of these aggresomes is part of a cellular defence
mechanism against misfolded proteins [14], and it can be
inhibited by drugs that depolymerize microtubules [15, 16].
Tubulin undergoes various posttranslational modifi-
cations including polyglutamylation, polyglycylation, car-
boxyterminal cleavage, and acetylation [17, 18]. Acetylation
is unique among the known tubulin modifications, in that it
occurs on the lysine 40 of α-tubulin which can be found on
stable microtubules in most cell types [19]. The deacetylation
of the lysine residue in tubulin is catalyzed by enzymes
called histone deacetylases (HDACs). In contrast, histone
acetyltransferases (HATs) transfer acetyl groups to lysine
residue to increase acetylation of tubulin [20]. This results
in a balance between acetylation and deacetylation states of
tubulin, and any shift in this balance results in changes in the
regulation of tubulin function [21]. The HDAC6 is the major
cytoplasmic tubulin deacetylase [21–23]. Moreover, it eﬃ-
ciently binds mono- and polyubiquitin molecules [24–26].
One interesting role of tubulin and tubulin modifying
deacetylases is their influence on aggregation of misfolded
proteins [12]. HDAC6 contributes to the degradation of
aggregated proteins because it is able to bind to both poly-
ubiquitinated and dynein motor proteins as an adaptor pro-
tein to help transport misfolded proteins along microtubules
into aggresomes which are finally degraded by autophagy
[13, 22, 27–29]. HDAC6 is able to sense ubiquitinated
cellular aggregates and consequently induces the expression
of major cellular chaperones by triggering the dissociation
of a repressive HDAC6/HSF1 (heat-shock factor 1)/HSP90
(heat-shock protein 90) complex and subsequent HSF1
activation. HDAC6 therefore appears as a master regulator
of the cell protective response to cytotoxic protein aggregate
formation [13].
We have recently shown that proteasome inhibition
evoked perinuclear protein accumulation which then leads
to the autophagy-mediated removal of the deposits [29].
In the present study, we demonstrate that Hsp90 inhibition
with geldanamycin can eﬀectively decrease the proteasome
inhibitor-induced aggregation. Increased tubulin acetylation
was observed in response to Hsp90, proteasome, and HDAC
inhibition, but the acetylation level was not correlated
with the amount of the aggregates in the ARPE-19 cells.
However, the tubulin polymerization state did influence the
localization of the aggregates.
2. Materials and Methods
2.1. Cell Culture and Treatments. Human retinal pigment
epithelial cells (ARPE-19, from ATCC, [30]) were used in
this study. The cells were grown in Dulbecco’s MEM/Nut
MIX F-12 (1 : 1) medium (Life Technologies, Paisley, UK)
containing 10% fetal bovine serum (Hyclone, Logan, UT,
USA), 2 mM L-glutamine (Cambrex, Charles City, IA,
USA), 100 units/ml penicillin (Cambrex), and 100 μg/ml
streptomycin (Cambrex). Before any exposure, the cells
were grown to confluency in a standard incubator (10%
CO2, +37◦C). Proteasome inhibition was accomplished
with 5 μM MG-132 (Calbiochem, San Diego, CA, USA).
Geldanamycin (GA, Calbiochem), at 0.25 μM concentration,
was used to inhibit the function of Hsp90. Microtubules were
acetylated with 1 μM trichostatin A (TSA; Sigma-Aldrich,
Steinheim, Germany). Taxol (TAX, Paclitaxel; Calbiochem),
at 1 μM concentration and nocodazole (NOC; Calbiochem),
at 5 μM concentration, were used to disrupt to function of
microtubules. The cells were exposed to the GA, TSA, TAX,
or NOC for 24 h, simultaneously with MG-132 for 24 h or
allowed to recover after 24 h MG-132 insult in medium with
or without chemicals (GA, TSA, TAX or NOC).
2.2. Phase Contrast Microscopy. Phase contrast microscopy
photographs were taken from live cells with a Nikon Eclipse
TE300 (Nikon, Tokyo, Japan) microscope.
2.3. Electron Microscopy. For transmission electron micro-
scopy (TEM), the cell culture samples were prefixed in
2.5% glutaraldehyde (in 0.1 M phosphate buﬀer, pH 7.4)
for 2 hrs at room temperature, followed by washing (15 min
in 0.1 M phosphate buﬀer). The samples were postfixed
in 1% osmium tetraoxide (in 0.1 M phosphate buﬀer) for
1 hr at room temperature and washed as before prior to
standard ethanol dehydration. Subsequently, the samples
were infiltrated and embedded in LX-112 resin (Ladd
Research Industries, Burlington, VT, USA). Polymerization
was carried out at 37◦C for 24 hrs and at 60◦C for 48 hrs.
The sections were examined in a JEOL-1200EX transmission
electron microscope (Jeol, Tokyo, Japan) at 80 kV.
2.4. Western Blotting. Exposed cells were lysed in M-Per
lysis buﬀer (Thermo Scientific, Waltham, MA, USA). Protein
concentrations were analysed with the Bradford (Coomassie
Brilliant Blue dye) method [31]. Whole cell extracts (20 μg of
protein) were run in 10% or 15% SDS-PAGE gels and then
wet blotted to nitrocellulose membranes (GE Healthcare,
Little Chalfont, Buckinghamshire, UK). The membranes
were blocked for 1 hour in 3% fat-free dry milk in 0.3%
Tween 20/PBS at room temperature (RT). Thereafter, the
membranes were incubated for 1 hour at RT with rabbit
polyclonal ubiquitin antibody (DakoCytomation, Glostrup,
Denmark, cat. no. Z 0458) or rat monoclonal Hsp90
antibody (Assay Designs, Ann Arbor, MI, USA, cat. no. SPA-
835) or mouse monoclonal Hsp70 antibody (Assay Designs,
cat. no. SPA-810) or rat monoclonal Hsc70 antibody (Assay
Designs, cat. no. SPA-815) or rabbit polyclonal LC3 antibody
(Abgent, San Diego, CA, USA, cat. no. AP1802a) except for
monoclonal acetylated tubulin antibody (Sigma-Aldrich, cat.
no. T6793) where the incubation was for 30 minutes at RT.
Primary antibodies were diluted (1 : 500, 1 : 5 000, 1 : 5 000,
1 : 5 000, 1 : 250 or 1 : 8 000 resp.) in 0.5% bovine serum
albumin in 0.3% Tween 20/PBS except for acetylated tubulin
which was diluted in 1% fat-free dry milk in 0.05% Tween
20/PBS. After 3×5 minutes washes with 0.3% Tween 20/PBS
(for acetylated tubulin 0.05% Tween 20/PBS) the membranes
were incubated for one hour at RT with horseradish
peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG
antibodies or anti-rat IgG antibodies (GE Healthcare).
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Figure 1: (a) Phase contrast micrographs of control (C) cells, and cells exposed to 5 μM MG-132 (MG) or 0.25 μM geldanamycin (GA) or
1 μM trichostatin A (TSA) or 1 μM taxol (TAX) or 5 μM nocodazole (NOC) for 24 hours. In addition, the cells were treated simultaneously
with GA or TSA or TAX or NOC and MG-132 for up to 24 hours, (b) and then allowed to recover under the indicated conditions for 24
hours. Protein aggregates are seen as dark granular deposits in perinuclear space (downward arrows), the examples of clear cytoplasm are
marked with upward arrows. Arrows from left to right indicate disperse aggregation.
The secondary antibodies were diluted (for ubiquitin
1 : 20 000, for Hsp90 1 : 10 000, for Hsp70 1 : 40 000, for
Hsc70 1 : 15 000 and for LC3 1 : 5000, resp.) in 3% fat-free
dry milk in 0.3% Tween 20/PBS except for acetylated tubulin
(1 : 6 000) which was diluted in 1% fat-free dry milk in 0.05%
Tween 20/PBS. Before detection, all of the membranes were
washed as before. Protein antibody complexes were detected
with an enhanced chemiluminescence method (Millipore,
Billerica, MA, USA). The western blots were quantified with
Quantity One software 4.5.0. (Bio-Rad, Hercules. CA, USA).
3. Results and Discussion
3.1. Hsps and Protein Aggregation. The ARPE-19 cells were
either nonstressed, or exposed to drugs, that is, 5 μM MG-
132 or 0.25 μM geldanamycin, 1 μM trichostatin A or 1 μM
taxol or 5 μM nocodazole for 24 hours. In addition, the cells
were treated simultaneously with MG-132 in conjunction
with geldanamycin, trichosatin A, taxol or nocodazole up
to 24 hours. Only a single MG-132 insult or combination
treatment with taxol induced a typical perinuclear aggre-
gation in ARPE cells (Figures 1(a) and 2(a)). Interestingly,
Hsp90 inhibition with geldanamycin eﬀectively suppressed
MG-132 induced protein aggregation. HDAC inhibition with
trichostatin A or tubulin depolymerization with nocodazole
evoked dispersed the mid-peripherical aggregation process
during proteasome inhibition. With all of the insults, cyto-
plasm underwent a similar eﬀective aggregation clearance
when exposed to MG-132 for 24 hours and then allowed to
recover for 24 hours in normal cell culture medium (Figures
1(b) and 2(b)).
A robust elevation of Hsp70 protein expression was
seen in response to MG-132 or geldanamycin exposures
(Figure 3). Hsp90 levels were not markedly aﬀected by the
4 Journal of Biomedicine and Biotechnology
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Figure 2: (a) Transmission electron micrographs of control (C) cells, and cells exposed to 5 μM MG-132 (MG) or 0.25 μM geldanamycin
(GA) or 1 μM trichostatin A (TSA) or 1 μM taxol (TAX) or 5 μM nocodazole (NOC) for 24 hours. In addition, the cells were treated
simultaneously with GA or TSA or TAX or NOC and MG-132 for up to 24 hours, (b) and then allowed to recover under the indicated
conditions for 24 hours.
treatments. Abrogation of proteasome-mediated protein
degradation caused a clear increase in the amount of Hsp70
which has a cytoprotective capacity in the MG-132-treated
ARPE-19 cells [29]. The classical transcriptional heat-shock
gene induction is attributable to the activation of HSF1
transcription factor [32]. In the activation process Hsp90
and Hsp70 dissociate from HSF1 transcription factor
[33, 34]. Geldanamycin has been shown to bind Hsp90, to
inhibit its function and to elicit the Hsp90 client protein
degradation in proteasomes [35, 36]. In line with previous
studies [37–39], the geldanamycin was found to trigger
a strong expression of Hsp70, while the Hsp90 response
remained weaker. The response is likely mediated through
HSF1 transcriptional activation [33, 34]. The increase in the
amount of inducible Hsp70 might be one of the regulators
suppressing the proteasome inhibitor-induced aggregation
process [29], when Hsp90 is simultaneously inhibited. It has
also been documented that a Hsp90 inhibitor may prevent
the aggregation of protein by regulating client protein
posttranslational modifications [40]. Since Hsp90 inhibition
has been reported to trigger autophagy clearance [41, 42],
we wished to analyze the autophagy induction marker
LC3 I/II levels in ARPE cells treated with geldanamycin or
MG-132 solely or both together for 6, 12, and 24 hours.
Our findings clearly show that proteasome inhibition mildly
induced autophagy, when related to LC3 II levels, but this
was not involved in geldanamycin treatments (Figure 4).
This indicates that autophagy clearance is not implicated in
the suppression of protein aggregation during Hsp90 and
proteasome inhibition in the ARPE-19 cells.
3.2. Ubiquitination. Cellular ubiquitin-protein (Ub) conju-
gate levels were analyzed by western blotting from cells
treated as described above. The level of Ub conjugation
was not changed by geldanamycin, trichostatin A, taxol,
or nocodazole treatment, but a very intensive induction of
Journal of Biomedicine and Biotechnology 5
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Figure 3: (a) Total proteins (20 μg) of whole cell extracts were examined by western blot using antibodies against ubiquitin, Hsp90, Hsp70,
acetylated tubulin, and Hsc70 of control (C) cells, and cells exposed to 5 μM MG-132 (MG) or 0.25 μM geldanamycin (GA) or 1 μM
trichostatin A (TSA) or 1 μM taxol (TAX) or 5 μM nocodazole (NOC) for 24 hours. In addition, the cells were treated simultaneously
with GA or TSA or TAX or NOC and MG-132 for up to 24 hours and then allowed to recover under the indicated conditions for 24 hours.
Hsc70 was used to check the equal loading of proteins. (b) Quantifications of western blots.
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Figure 4: (a) Total proteins (20 μg) of whole cell extracts were examined by western blot using antibodies against LC3 of control (med) cells,
and cells exposed 0.25 μM geldanamycin (GA) or 5 μM MG-132 (MG) or their combination for 6, 12, and 24 hours. Tubulin was used to
check the equal loading of proteins. (b) Quantifications of western blots and LC3 II/I ratio.
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ubiquitination was seen in response to MG-132 exposure
whether geldanamycin, trichostatin A, taxol, or nocodazole
were present or not (Figure 3). Inhibition of Hsp90 therefore
seems to have only a minor impact on the level of ubiq-
uitination in the ARPE-19 cells, although Hsp90 has been
shown to regulate both proteasomal and autophagy clearance
through its client proteins [41–43]. The ubiquitin levels were
slightly reduced when proteasome inhibition was removed
and the cells recovered either with geldanamycin, trichostatin
A, taxol, or nocodazole compared to incubations of MG-132
together with these chemicals. This is apparently explained
by the autophagic clearance of proteasome-inhibitor-in-
duced aggregates, as we have recently documented [29].
3.3. Acetylation. Protein aggregates formed at the cell
periphery are delivered along the microtubulus network by
dynein-dependent retrograde traﬃcking to a juxtanuclear
location where they form aggresomes [11, 12]. The reversible
acetylation of α-tubulin has been linked to the regulation of
microtubule stability and function [21]. Decreased tubulin
acetylation has been shown in some reports to reduce
microtubule stability [21, 22], but in other experiments
no association was observed [44, 45]. HDAC6 deacetylates
tubulin, and Hsp90, and forms complexes with many other
proteins, including ubiquitinated proteins. HDAC6 also
interacts with a component in the dynein-dynactin micro-
tubule motor complex and regulates protein aggregation
traﬃcking [13, 45, 46]. Trichostatin A is a classical inhibitor
of HDAC deacetylase activity and thus it also blocks the
HDAC6 [47]. The phase contrast and transmission electron
microscopic analysis revealed dispersed cytoplasmic aggrega-
tion in response to simultaneous treatment of trischostatin A
or nocodazole and proteasome inhibition (Figures 1 and 2).
Trichostatin A evoked a clear increase in tubulin acetylation
levels, while in the situation of tubulin depolymerizator
induced by nocodazole, tubulin acetylation remained at
control level (Figure 3). In contrast, a tubulin stabilizer,
taxol induced tubulin acetylation that was not, however,
as extensive as that evoked by trichostatin A. Hsp90 and
proteasome inhibition evoked a similar slight increase in
the tubulin acetylation levels. All these findings indicate that
total tubulin acetylation is not related to perinuclear aggrega-
tion. The HDAC inhibition by trichostatin A probably aﬀects
the dynein motor and regulates aggregation localization, but
does not prevent the formation of aggregates. Moreover, the
polymerization state of tubulin regulates the localization of
proteasome inhibitor-induced aggregates, but this process
cannot be estimated by measuring total tubulin acetylation
levels. Hsp90 inhibition seems to prevent aggregation rather
than regulating traﬃcking through the tubulin network.
4. Conclusions
Hsp90 inhibition is eﬀectively involved in the regulation of
protein aggregation that is independent of HDAC inhibition
or tubulin acetylation levels in the RPE cells. These findings
open new perspectives for understanding the pathogenesis of
protein aggregation in retinal cells, and they may be useful in
the development of therapeutic treatments to prevent retinal
cell deterioration, that is, during aging.
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